JPRN-UMIN000006346已完成2 期
Phase II clinical trial of dasatinib in newly diagnosed chronic phase chronic myelogenous leukemia - Phase II trial of dasatinib for newly diagnosed CP-CML.
Ph leukemia trial Group0 个研究点目标入组 50 人开始时间: 2011年10月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Patients who are true with either of the followings are excluded; (1)A case with the double cancer of the activity. (2)Females during pregnancy or lactation. (3)Patients with no will or capability to use appropriate birth control during the trial. (4)Other serious past disease history or present concomitant diseases that are considered inappropriate to conduct this trial. (5)Past history of tyrosine kinase inhibitor therapy. (6)The patients of accelerated phase or blast phase clearly. (7)The patients with positive one of HBs antigen, HCV antibody, HIV antibodies
研究者
相似试验
进行中（未招募）
不适用
Phase II efficacy and safety study of Dasatinib in Patients with Chronic and Accelerated Phase Chronic Myeloid Leukaemia Relapsing after Allogeneic Blood or Bone Marrow Transplantation - CML DASATINIBchronic myeloid leukaemiaMedDRA version: 9.1Level: LLTClassification code 10009013Term: Chronic myeloid leukaemiaEUCTR2008-001361-29-GBEBMT (European group for Blood and Marrow Transplantation)50
进行中（未招募）
不适用
Phase II efficacy and safety study of Dasatinib in Patients with Chronic and Accelerated Phase Chronic Myeloid Leukaemia Relapsing after Allogeneic Blood or Bone Marrow TransplantatioEUCTR2008-001361-29-FREBMT (European group for Blood and Marrow Transplantation)50
进行中（未招募）
不适用
Phase II efficacy and safety study of Dasatinib in Patients with Chronic and Accelerated Phase Chronic Myeloid Leukaemia Relapsing after Allogeneic Blood or Bone Marrow Transplantation - CML DASATINIBchronic myeloid leukaemiaMedDRA version: 9.1Level: LLTClassification code 10009013Term: Chronic myeloid leukaemiaEUCTR2008-001361-29-DEEBMT (European group for Blood and Marrow Transplantation)50
招募中
2 期
Phase II clinical trial of low dose dasatinib in patients with resistant or intolerant chronic myeloid leukemia who are treated with low lose imatinibChronic myeloid leukemia patients in chronic phase who are refractory or resistant to low dose imatinib therapy.JPRN-UMIN000003499Kanto CML Study Group30
进行中（未招募）
1 期
Phase II trial of dasatinib in subjects with advanced cancers harboring DDR2 mutation or inactivating B-RAF mutatioCarcinoma, Non-small cell lungMedDRA version: 14.1 Level: LLT Classification code 10007284 Term: Carcinoma System Organ Class: 100000004864MedDRA version: 14.1 Level: LLT Classification code 10053571 Term: Melanoma System Organ Class: 100000004864EUCTR2011-003128-11-GBBristol-Myers Squibb International Corporation19